Malignant Giant Cell Neoplasm
NCI Definition: A malignant neoplasm characterized by then presence of atypical giant cells. 
There are 2 clinical trials for malignant giant cell neoplasm, of which 2 are open and 0 are completed or closed. Of the trials that contain malignant giant cell neoplasm as an inclusion criterion, 2 are phase 2 (2 open).
Ipilimumab, nilotinib, and nivolumab are the most common interventions in malignant giant cell neoplasm clinical trials.
Significant Genes in Malignant Giant Cell Neoplasm
CD274 is an inclusion eligibility criterion in 1 clinical trial for malignant giant cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and malignant giant cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.